Which psychedelics are legal in the US in 2026 — ketamine, psilocybin, ayahuasca, and the FDA pipeline.
"Legal psychedelics" means different things in different contexts. Legal for whom, where, in what setting, and under what framework matters significantly. The table below maps US legal status by substance as of May 2026 — but read the substance sections for what access actually looks like in practice.
| Substance | US Federal Status | Where Accessible (US) | Easiest Legal Access |
|---|---|---|---|
| Ketamine | Schedule III | All 50 states (clinics + telehealth) | Oral ketamine via telehealth platform (prescription, mailed lozenges, remote sessions) |
| Psilocybin | Schedule I | Oregon (licensed centers), Colorado (healing centers) | Oregon service center — no prescription needed, 21+ |
| Ayahuasca (DMT) | Schedule I | 4 DEA-exempted religious churches (US); widely abroad | UDV or Santo Daime ceremony (if you qualify); or Peru/Netherlands retreats |
| MDMA | Schedule I | FDA clinical trials only | Enroll in a MAPS-successor or university MDMA trial (ClinicalTrials.gov) |
| LSD | Schedule I | MindMed MM120 Phase 3 trials only | Enroll in MindMed's Voyage or Panorama trials (GAD indication) |
| Ibogaine | Schedule I | FDA-IND trials (Texas IMPACT) only | Licensed clinics in Mexico (not subject to US law) |
| 5-MeO-DMT | Schedule I | GH Research GH001 trials (select sites) | Retreat in Costa Rica or Mexico (not subject to US law) |
| Mescaline (peyote) | Schedule I* | Native American Church members (federal statutory exemption) | N/A — NAC exemption is for enrolled tribal members, not the general public |
| Mescaline (non-peyote) | Schedule I | Colorado (decriminalized personal possession, Prop 122) | Colorado only — no licensed program for mescaline (non-peyote) yet |
Ketamine is the outlier: it is Schedule III (not Schedule I), and it has an FDA-approved product. Spravato (esketamine nasal spray) was approved in 2019 for treatment-resistant depression (TRD) and in 2020 for major depressive disorder with acute suicidal ideation. Spravato requires in-office administration and a 2-hour observation period at a certified healthcare setting.
Off-label IV/IM/sublingual ketamine is also widely prescribed through ketamine clinics and, increasingly, telehealth platforms that mail oral ketamine lozenges with remote monitoring sessions. This is currently the most cost-effective and accessible psychedelic-adjacent therapy in the US.
Cost range: Spravato with insurance may cost $10–$100/session (but requires in-office administration). IV ketamine at clinics: $400–$800/infusion. Telehealth ketamine (oral): $150–$300/month including lozenges and sessions. Full ketamine guide →
Psilocybin is the most researched classical psychedelic and the most likely next substance to achieve broader legal access in the US. Two legal pathways exist:
In all other US states, psilocybin remains Schedule I. The FDA has granted Breakthrough Therapy designation to both COMPASS Pathways and Usona Institute for psilocybin — Phase 3 trials are ongoing. Full psilocybin guide →
DMT — the active compound in ayahuasca — is Schedule I. The Religious Freedom Restoration Act (RFRA), as interpreted by the Supreme Court in Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006), permits four specific US religious organizations to use ayahuasca in genuine religious ceremonies:
Outside these four organizations, ayahuasca is illegal in the US. Most US residents legally access ayahuasca through retreats in Peru, Costa Rica, the Netherlands, or Jamaica. Full ayahuasca guide →
MDMA-assisted therapy has the strongest published evidence for PTSD of any psychedelic, but the FDA rejected Lykos Therapeutics' NDA in August 2024, citing issues with the trial design, blinding, and functional unblinding. A new Phase 3 trial is required before MDMA can be prescribed legally in the US.
Australia is currently the only country where psychiatrists can legally prescribe MDMA for PTSD via TGA's Authorised Prescriber scheme. Access is limited and expensive (~$25,000 AUD per course of treatment).
In the US, legal access is possible only through FDA-approved clinical trials. Search ClinicalTrials.gov for "MDMA PTSD" to find recruiting studies. Full MDMA guide →
The most significant near-term developments as of 2026:
Yes — for psilocybin in Oregon and Colorado. Licensed service centers and healing centers offer structured experiences with trained facilitators. These are not "retreats" in the informal sense; they are licensed facilities operating under state regulation with specific protocols, preparation requirements, and post-session integration support.
For other psychedelics, retreats operating legally must be outside the United States. Common legal retreat destinations:
In most US states: no. Microdosing psilocybin mushrooms or LSD involves possession of a Schedule I substance, regardless of the quantity or intended use. The size of the dose does not change the legal classification.
In Colorado, personal possession of psilocybin in any quantity for personal use is decriminalized under Prop 122. In Denver specifically, a 2019 ordinance similarly deprioritizes enforcement. In 30+ other US cities with deprioritization resolutions, local police treat enforcement as lowest priority — but state and federal law still apply.
Amanita muscaria products (containing muscimol, not psilocybin) are not federally scheduled and are legally available in most US states. They are chemically and experientially distinct from classic psilocybin mushrooms.
Ketamine is the only psychedelic-adjacent substance that is both federally legal and widely accessible — it is Schedule III and has an FDA-approved product (Spravato). Psilocybin is legal in licensed programs in Oregon and Colorado. Ayahuasca (DMT) is legal only for members of four DEA-recognized religious churches. MDMA, LSD, ibogaine, and 5-MeO-DMT are Schedule I with no approved US use; access is limited to clinical trials.
Yes. Ketamine is Schedule III (not Schedule I) and has FDA-approved uses: Spravato (esketamine) for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Off-label IV/IM/sublingual ketamine is also widely prescribed by clinics nationwide and via telehealth. Whether ketamine is a 'psychedelic' is debated — it is classified as a dissociative, not a classical 5-HT2A agonist — but it is the most accessible legal psychedelic-adjacent substance in the US.
Yes — in Oregon and Colorado. Oregon's Measure 109 service centers have been operating since 2023; Colorado's Prop 122 healing centers are licensing. Both require on-site facilitation; you cannot take psilocybin product home. In all other states, psilocybin is Schedule I and illegal.
Yes, for psilocybin only. Oregon and Colorado both have licensed service center / healing center programs where adults 21+ can receive facilitated psilocybin sessions legally. For other psychedelics (ayahuasca, ibogaine, 5-MeO-DMT), legal retreats operate outside the US — in Jamaica, Peru, Netherlands, Mexico, and Costa Rica.
In most US states, no. Microdosing psilocybin or LSD involves possession of a Schedule I substance regardless of the dose. Colorado decriminalized personal psilocybin possession under Prop 122. About 30 US cities have deprioritization resolutions, but these do not make microdosing legal — state and federal law still apply.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.